leisure time -WSS

leisure time

author：knowledge 2025-09-14 11:51:35 - browse：3

A photo of Robert Blum speaking at the STAT Summit West on May 16, 2024 — Cytokinetics CEO Robert Blum spoke Thursday at a talk during STAT’s Breakthrough Summit West in San Francisco. Sarah Gonzalez for STAT

As Cytokinetics faces pressure to sell itself to a large pharma company following positive late-stage results of its heart drug, CEO Robert Blum maintains that the biotech can launch the treatment — what would be its first approved medication — on its own.

Cytokinetics reported top-line results of its drug, aficamten, in obstructive hypertrophic cardiomyopathy, or oHCM, last December, sending its shares up on speculation the company would get acquired. Full Phase 3 results released this week further suggest the drug could be used more flexibly than a similar treatment sold by Bristol Myers Squibb, but investors have questioned whether the biotech has the resources and salesforce to compete with a large pharma company.

Blum, speaking Thursday at a talk during STAT’s Breakthrough Summit West, said that if prospective buyers approach the company, he will talk to them, but “at the same time, we’re pushing forward, as we always have, with the original intention to build a commercial business. And that’s not something new. That’s not something that’s a result of a failed M&A dialogue.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Medicare Advantage enrollment hits roughly 33.4 million

WSS

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

New study raises questions about niacin and heart health

NYU Langone launches private ChatGPT for its health care data

Medicare Advantage enrollment grows 7.1% to 33.4 million people

MD Anderson's Padmanee Sharma responds to research credit suit

Medicare Advantage enrollment hits roughly 33.4 million

Wikipedia

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Moonlake's readout produced a cash windfall. Risks remain

How to make Best Hospitals ratings actually useful for patients

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Abridge raises $150m as clinical notes automation market heats up

Medical leaders decry Supreme Court decision on affirmative action

Feds fine Medicare Advantage plans for overcharging members

Tori Bowie and the unacceptable rates of Black maternal death

How to make AI work for medicine

Moonlake's readout produced a cash windfall. Risks remain

How a symptom of dementia informs our understanding of creativity

focus

New study raises questions about niacin and heart health

Hospitals are piloting generative AI tools as regulators play catch

How to make AI work for medicine

Diversity in medical illustrations gets boost from Chidiebere Ibe

Medicare Advantage enrollment grows 7.1% to 33.4 million people

Flagship Pioneering startup Sonata Therapeutics lays off 21

focus

knowledge

leisure time

leisure time